主页
市场
图表与思路
Algo
新闻
Store
经纪商
下载
经济日历
交易信号
网页端
键入
/
进行搜索:@user,$symbol
查找
登录
创建账户
Deutsch
English
Русский
中文
Español
Português
日本語
한국어
Français
Italiano
Türkçe
ITRM
#3825
Iterum Therapeutics plc Ordinary Share
0.2
6
+13.04%
版块:
基础:
利润货币:
日范围
年范围
日变化
+13.04%
每月变动
-21.21%
6个月变化
-63.38%
年变化
-80.60%
前一天收盘价
0.2
3
Open
0.2
6
Bid
Ask
Low
0.2
6
High
0.2
6
交易量
2
市场
股票
医疗保健
ITRM
Open full chart
Financials
Overview
声明
Statistics
Dividends
Quarterly
Annual
Value
2020
2021
2022
2023
2024
TTM
Key stats
Total common shares outstanding
11.77 M
12.19 M
12.71 M
16.43 M
34.58 M
—
Valuation ratios
Enterprise value
—
—
-9.4 M
26.37 M
37.08 M
—
Price to earnings ratio
—
—
-0.25
-0.67
-1.4
-4.91
Price to sales ratio
—
—
—
—
—
—
Price to cash flow ratio
—
—
-0.61
-0.65
-1.3
-5.47
Price to book ratio
—
—
0.4
-4
-8.54
-11.42
Enterprise value to EBITDA ratio
—
—
—
—
—
—
Profitability ratios
Return on assets %
1.59
1
0.66
1.46
0.56
0.76
Return on equity %
1.03
1.82
1.59
5.99
6.07
6.42
Return on invested capital %
354.99
284.57
960.67
4 974.98
420.29
390.3
Gross margin %
—
—
—
—
—
—
Operating margin %
—
—
—
—
—
—
EBITDA margin %
—
—
—
—
—
—
Net margin %
—
—
—
—
—
—
Liquidity ratios
Quick ratio
0.51
6.43
6.89
1.89
1.41
9.46
Current ratio
0.51
6.43
6.89
1.89
1.41
9.96
Inventory turnover
—
—
—
—
—
—
Asset turnover
0
0
—
—
—
—
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
0.68
0.08
0.15
0.44
0.7
2.52
Long term debt to total equity ratio
0.44
0.14
0.36
1.79
7.65
23.41
Per share metrics
Operating cash flow per share
—
—
1.51
3.03
1.36
0.59
EBIT per share
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
Cash per share
—
—
4.97
1.85
1.22
2.16
Net current asset value per share
—
—
5.1
1.97
1.26
2.33
Tangible book value per share
—
—
2.15
0.49
-0.8
-1.92
Working capital per share
—
—
4.36
0.93
0.36
1.05
Book value per share
—
—
2.29
0.49
0.21
0.54
新闻
Iterum Therapeutics erweitert Medicare-Zugang für Antibiotikum ORLYNVAH
Iterum Therapeutics expands Medicare Part D access for ORLYNVAH
Iterum Therapeutics expands market access for ORLYNVAH antibiotic
Iterum Therapeutics sichert wichtige PBM-Vereinbarung für Antibiotikum ORLYNVAH
Iterum Therapeutics secures major PBM agreement for antibiotic
NASDAQ-Notierung in Gefahr: Iterum Therapeutics verstößt gegen Zulassungsregeln/n
Iterum Therapeutics receives Nasdaq notice on listing compliance
Iterum Therapeutics erweitert Kostenerstattung für Antibiotikum ORLYNVAH in den USA
Iterum Therapeutics expands reimbursement coverage for ORLYNVAH
Iterum’s antibiotic ORLYNVAH now available through McKesson
Iterum Therapeutics director Dunne buys $2,191 in shares
Iterum Therapeutics plc (ITRM) Q3 2025 Earnings Call Transcript